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Summary
Background—Hemophilia A (HA) is an X-linked bleeding disorder caused by a deficiency in 
factor VIII (FVIII). von Willebrand disease (VWD) is characterized by a quantitative or 
qualitative defect in von Willebrand Factor (VWF). Patients with VWD with severely low VWF 
or VWD Type 2N (VWD2N), a VWD subtype distinguished by defective VWF binding to FVIII, 
may have reduced FVIII levels secondary to their VWD. These patients superficially resemble 
patients with HA, and pose a potential for misdiagnosis.
Objectives—Investigate the unexplained cause of bleeding in HA patients without known FVIII 
mutations by assessing plasma VWF antigen (VWF:Ag), FVIII binding capacities, and VWF 
genotypes.
Patients/Methods—Thirty-seven of 1027 patients with HA studied as part of the Hemophilia 
Inhibitor Research Study lacked identifiable F8 mutations. These patients (cases) and 73 patients 
with identified F8 mutations (controls) were evaluated for VWF:Ag, patient's VWF capacity to 
bind FVIII (VWF:FVIIIB), and VWF sequence.
Results—Four cases had VWF:Ag <3 IU/dL and VWF mutations consistent with Type3 VWD. 
Six cases and one control were heterozygous for mutations previously reported to cause Type1 
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VWD (VWD1) (n=5 cases and 1 control) or predicted to be deleterious by Polyphen2 and SIFT 
prediction tools (n=1 case). One control had VWF:Ag <30 IU/dl, and seven patients (4 cases and 3 
controls), including two cases who were heterozygous for a known VWD2N mutation, had 
reduced VWF:FVIIIB.
Conclusions—These data emphasize that some patients diagnosed with HA require VWF 
assessments in order to achieve a comprehensive diagnosis and an optimal treatment strategy.
Introduction
Although more than 2,500 F8 mutations have been described(1), large Hemophilia A (HA) 
cohorts usually include a subset of patients for whom F8 mutations are not identified(2;3). 
The differential diagnosis for HA includes von Willebrand disease (VWD), an autosomal 
bleeding disorder characterized by a deficiency in von Willebrand factor (VWF). VWF, a 
glycoprotein with a diverse set of hemostatic properties (reviewed in(4)), plays a pivotal role 
in recruiting platelets to sites of vascular injury and serves as a carrier protein for FVIII in 
plasma, acting both to stabilize bound FVIII and to sequester it from its procoagulant 
functions(5;6). Dissociation of FVIII from VWF is facilitated by cleavage of FVIII at three 
sites by thrombin, a process that also results in FVIII activation(7), and by the binding of 
VWF to exposed collagen at sites of vascular injury(8). Following its release from VWF, 
activated FVIII (FVIIIa) binds to anionic phospholipid surfaces where it forms a complex 
with activated Factor IX to promote Factor X activation(9) leading to downstream thrombin 
generation and clot formation. FVIIIa inactivation occurs by spontaneous dissociation of its 
A2 subunit(10) and via proteolysis by activated protein C(11), mechanisms that act together 
to guarantee FVIII's short plasma half-life when unbound to VWF.
Bleeding phenotypes in VWD are heterogeneous and most frequently include menorrhagia, 
bleeding from minor wounds, and (muco)cutaneous bleeding(12). Most forms of VWD can 
be distinguished from HA by measurement of VWF antigen (VWF:Ag) levels and ristocetin 
cofactor or other measures of VWF activity. VWD Types 1 and 3 (VWD1 and VWD3) 
manifest as partial and complete quantitative VWF deficiencies, respectively(4). Type 2 
VWD (VWD2) is characterized by a qualitative defect that causes patients to express mildly 
reduced or normal levels of structurally abnormal VWF(4;13), including VWD Type 2N 
(VWD2N), which features a structural defect in VWF that impedes FVIII binding(14). In the 
absence of the stabilizing effects of VWF, patients with VWD3 and VWD2N homozygotes 
and compound heterozygotes have low plasma levels of FVIII(15), and, therefore present as 
clinically similar to patients with HA. The overlap of clinical features in these two patient 
groups can lead to persons with VWD being misdiagnosed as having HA(16;17) and 
potentially receiving suboptimal treatment.
In a large sample of patients with HA studied as part of the Hemophilia Inhibitor Research 
Study (HIRS) conducted by the Centers for Disease Control and Prevention (CDC), 37 
(3.6%) of 1027 patients had no identified F8 mutation. The current study examines plasma 
VWF antigen (VWF:Ag) and FVIII binding capacity (VWF:FVIIIB) and analyzes VWF for 
coding mutations in these 37 cases in order to identify VWD patients misdiagnosed with 
HA.
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Methods
Subjects—Patients with HA were enrolled in HIRS conducted at 17 U.S. hemophilia 
treatment centers between 2006 and 2013. The cohort in the current study (Table 1) includes 
and expands on an HA cohort previously described in a prospective surveillance study for 
inhibitors(18) and consists of 37 HA patients without identified F8 exon or intron/exon 
boundary mutations (cases) and 65 consecutively enrolled, non-severe HA patients with 
known F8 mutations (controls).
Quantitation of vWF binding capacity for FVIII—Blood was prepared and shipped to 
CDC as previously described (3). VWF:Ag was measured by latex immunoassay 
(Diagnostica Stago, Parsippany, NJ), and VWF:FVIIIB was determined for plasma samples 
normalized for VWF:Ag using a commercially available enzyme-linked immunosorbent 
assay (ELISA) as described by the manufacturer (Diagnostica Stago, Parsippany, NJ).
Molecular methods—Type O versus non-O blood groups were inferred by genotyping 
the frameshift-causing single base deletion in the ABO gene (rs8176719) using a TaqMan 
custom SNP assay as directed by the manufacturer (Applied Biosystems, Carlsbad, CA) and 
reported elsewhere(19). Each exon and +/- 20 base pairs of the adjacent intronic sequence of 
the VWF gene were targeted for next generation sequencing on an Illumina MiSeq system 
(Illumina, Inc., San Diego, CA). The presence of all pathological variants was verified by bi-
directional Sanger re-sequencing using a 3730 DNA analyzer (Applied Biosystems, 
Carlsbad, CA).
Results and Discussion
Determination of HA patient VWF plasma levels
Plasma from 37 cases (HA patients with no known F8 mutation) and 65 consecutively 
enrolled non-severe controls (HA patients with a known F8 mutation) (Table 1) was tested 
for VWF plasma levels (VWF:Ag), and patients were classified according to National Heart 
Lung and Blood Institute (NHLBI) guidelines(20). As shown in Table 2, 4 cases (10.8%) 
had VWF:Ag below the 3 IU/dL threshold for a diagnosis of VWD3. One subject (control 1) 
had VWF:Ag in the range for presumptive VWD1 or VWD2 (3-30 IU/dL), and low 
VWF:Ag levels (30-50 IU/dL) were observed in 5 cases (13.5%) and 4 controls (5.5%).
Capacity of Patient VWF to bind FVIII
A commercially available ELISA was used to measure the capacity of each subject's plasma 
VWF to bind to recombinant FVIII. Four cases and 3 controls had VWF:FVIIIB below 80% 
(Tables 2 and 4), which is the cutoff for healthy donors established by Veyradier et al.(21). 
Two of these four cases were heterozygous for p.R854Q (cases 10 and 13), a mutation 
reported to cause VWD2N (22). One case (case 9) was found to be heterozygous for a 
mutation identified in the 1000 Genomes Project(23) and predicted to be deleterious by 
Polyphen2(24) and SIFT(25) prediction tools (p.R2313C), while the other case did not have 
a detectable VWF mutation (case 15). The remaining 3 subjects with VWF:FVIIIB <80% 
were controls, including one who was heterozygous for VWF p.Y1584C (control 1), a 
Boylan et al. Page 3
J Thromb Haemost. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
mutation previously reported in patients with VWD1(22) and two others without a 
detectable VWF mutation (controls 11-12) (Tables 2 and 4).
Although both individuals with VWD2N mutations (cases 10 and 13) identified in the 
current study tested below the normal range for VWF:FVIIIB, only one (case 13) had a 
result within the range established by Veyradier et al. for VWD2N heterozygotes (30-65%)
(Table 2)(21). This discrepancy could be due to the fact that the VWD2N sample size used 
by Veyradier et al. to establish this range was relatively small (n=9) and may not accurately 
reflect the true range of VWF:FVIIIB binding in VWD2N heterozygotes using this assay. 
An additional patient of interest, case 15, lacks an identified mutation in either F8 or VWF 
and had VWF:FVIIIB of 63%. The underlying reason for this patient's low VWF:FVIIIB is 
unclear, but, in the Veyradier et al. study(21), a subset of patients with non-2N VWD or HA 
tested in this range. Future studies with a larger number of VWD2N heterozygotes are 
required to obtain a better estimate of the true VWF:FVIIIB range. However, given the low 
number of patients available and because the presence of a single copy of a VWD2N 
mutation is unlikely to serve as the causative factor for a patient's bleeding diathesis, 
establishing, with confidence, a range for VWD2N heterozygotes may be of limited utility. 
It may be more practical to expand the range for possible VWD2N heterozygosity to include 
all samples that test below a normal reference group for VWF:FVIIIB (<80%).
VWF genotypes of HA patients
Analysis of VWF gene sequence revealed that five patients had VWF sequence abnormalities 
that are known to cause a bleeding phenotype, including four cases who were homozygous 
or compound heterozygous for VWF nonsense or frameshift mutations. As shown in Table 3, 
case 3 has a homozygous frameshift mutation (p.P812Rfs*31) previously reported to cause 
VWD3(22), two patients (cases 1 and 2) are compound heterozygotes for previously 
reported VWF nonsense and frameshift mutations (p.R324X and p.P812Rfs*31), and one 
patient (case 4) is a compound heterozygote carrying p.W553Lfs*97(22) and p.A462Qfs*15 
(not previously reported) VWF frameshift mutations. As expected, these four patients were 
the same four who had VWF:Ag levels <3 IU/dL (Table 2). One additional patient (Control 
1), who has abnormally low VWF:Ag (28 IU/dL), is heterozygous for a VWF mutation 
previously reported to cause VWD1(22)(Tables 2 and 3).
Twenty-two additional patients who have less severe VWF abnormalities, which do not 
cause but may complicate the HA patient's bleeding phenotype, are shown in Table 4. Eight 
of these patients, including 5 cases (Cases 10-14) and three controls (Control 8-10), while 
having VWF:Ag≥50 IU/dL, had mutations previously reported to contribute to some form of 
VWD(22), and three additional subjects (case 9 and controls 6-7) had VWF polymorphisms 
that are predicted to be deleterious by PolyPhen2(24) and/or SIFT(25) amino acid 
substitution prediction tools. Eight subjects without identified deleterious VWF 
polymorphisms (cases 5-8 and controls 2-5) had reduced VWF:Ag levels (30-50 IU/dL), 
(Table 4); however, it is notable that seven of these eight individuals are blood type O, 
which is known to correlate with decreased plasma levels of VWF(26).
Distinguishing VWD from HA has important implications for patient treatment strategies 
and provides patients with meaningful information regarding the genetics behind their 
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disorder. Our data reemphasize the conclusions previously published by Mazurier et al.(27) 
and Gupta et al.(28) by highlighting that VWF phenotypes are relevant in patients presenting 
with low FVIII. Overlooking this possibility may lead to suboptimal treatment of bleeding 
episodes in a subset of patients. The data presented herein demonstrate that there was a low 
frequency of patient referrals included in the HIRS study (four subjects; 0.4% of enrolled 
patients) who were misdiagnosed with moderate HA but actually had VWD3. Moreover, 
although one of these patients was receiving plasma derived FVIII, which contains residual 
VWF, the other three had a HA product treatment history consisting solely of recombinant 
FVIII at study entry. In the absence of supplemental VWF, the FVIII infusions received by 
these patients with VWD3 were unlikely to control all bleeding episodes adequately. An 
additional patient diagnosed with mild HA (control 1) with a known F8 mutation (p.2150C) 
was found to also carry a mutation previously reported to cause VWD1 (Y1584C)(22). This 
subject had VWF:Ag of 28 IU/dL and 13 U/dL of FVIII activity, and, despite his VWF 
deficiency, was on a HA treatment regimen consisting exclusively of recombinant FVIII. 
Overall, of the 14 patients identified to have reduced VWF, only 2 had a treatment history 
that included a product that would elevate plasma VWF. These data suggest that there is a 
subset of patients with HA with low VWF in whom post-infusion FVIII responses should be 
evaluated in order to determine if they may benefit from the use of products containing 
VWF.
The NHLBI guidelines suggest reserving the definite diagnosis of VWD for patients with 
VWF:Ag < 30 IU/dL and classifying individuals with levels of 30-50 IU/dL as “low VWF”
(20). The current study identified nine case and control patients with mild to moderately 
reduced VWF:Ag (30-50 IU/dL). VWF levels are highly variable in healthy populations, 
and eight of the nine patients in our cohort who fall into the low VWF range have blood type 
O, which may account for the low expression levels. It is also possible that these patients 
have undetected VWF mutations or mutations in other gene(s) that affect VWF expression. 
The current study includes four patients (cases 5-8) in the low VWF range without an 
identified mutation in either F8 or VWF. An off target mutation indirectly affecting VWF 
expression may contribute to the bleeding diathesis in these patients, particularly in subjects 
with considerable levels of residual FVIII activity (cases 5 and 7). In addition, as shown 
recently by Pezekshhkpoor et al., low FVIII levels in HA patients without identified F8 
mutations may be caused deep intronic mutations in F8 that lead to alternative transcript 
splicing, which can cause frameshifts and low FVIII expression (29).
The current study identified five patients diagnosed with HA who have VWF mutations that 
play a causal role (Cases 1-4 and control 1) in their bleeding phenotype (Table 3). Twenty-
two additional HA patients (11 Cases and 11 controls; Table 4) were found to have genetic, 
quantitative, or qualitative VWF abnormalities that, despite not serving as the primary cause 
for the patient's bleeding phenotype, highlight the importance of tailoring treatment 
strategies to individual patients. The inclusion of analyses of VWF phenotype and genotype 
to supplement standard F8 analysis for patients diagnosed with HA will identify instances of 
misdiagnosis, but a proportion of patients may remain with no identified cause for their 
disease.
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Table 1
Age and family history of bleeding data from Hemophilia A patients with or without knownmutations.
Subjects
N
Mean Age at Study
Entry (Median)*
Family History of
Bleeding Disorder† %
Cases (Without F8 Mutation)
Severe HA 11 22.6 (15) 40
Non-Severe HA 26 22.8 (12)* 58.3
Controls (Without F8 Mutation)
Non-Severe HA 65 18.0 (11) 67.2
*Age at study entry is unknown for 1 non-severe case
†
Family history of bleeding is unknown for 4 controls, 1 severe case, and 2 non-severe cases.
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